Subgroup analyses of prescribed treatment groups in prevalent adult persons with alopecia areata in 2020 (n=4692)
| Treatment | Topicals | Systemic biologics | Systemic non-biologics | Systemic GCS* |
| Age (years), p value | <0.001 | 0.158 | <0.001 | <0.001 |
| Up to 30, n(%) | 393 (7.9) | 2 (0.0) | 250 (5.0) | 44 (0.9) |
| > 30–45, n(%) | 377 (7.6) | 1 (0.0) | 285 (5.7) | 64 (1.3) |
| > 45–65, n(%) | 590 (11.9) | 5 (0.1) | 576 (11.6) | 207 (4.2) |
| > 65, n(%) | 499 (10.0) | 0 (0.0) | 611 (12.3) | 215 (4.3) |
| Gender, p value | <0.001 | 0.471 | <0.001 | <0.001 |
| Male, n(%) | 559 (11.2) | 4 (0.1) | 370 (7.4) | 82 (1.6) |
| Female, n(%) | 1300 (26.2) | 4 (0.1) | 1352 (27.2) | 448 (9.0) |
| Insurance district types, p value | 0.002 | 0.272 | 0.723 | 0.588 |
| Urban, n(%) | 1315 (26.5) | 4 (0.1) | 1176 (23.7) | 365 (7.3) |
| Rural, n(%) | 543 (10.9) | 4 (0.1) | 543 (10.9) | 163 (3.3) |
| Specialist, p value | <0.001 | <0.001 | <0.001 | <0.001 |
| None of both, n(%) | 131 (7.0) | 2 (25.0) | 523 (30.4) | 187 (35.3) |
| General practitioner, n(%) | 367 (19.7) | 0 (0.0) | 1038 (60.3) | 255 (48.1) |
| Dermatologist, n(%) | 1184 (63.7) | 6 (75.0) | 116 (6.7) | 80 (15.1) |
| Both n(%) | 177 (9.5) | 0 (0.0) | 45 (2.6) | 8 (1.5) |
Bold values display significant differences.
*Subtype of non-biologics.
GCS, glucocorticosteroid.